DFTX
Definium Therapeutics, Inc. (DFTX) reported net income of -$183.79M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$183.79M | -69.1% |
| FY 2024 | -$108.68M | -13.5% |
| FY 2023 | -$95.73M | -68.6% |
| FY 2022 | -$56.80M | +39.0% |
| FY 2021 | -$93.04M | -174.1% |
| FY 2020 | -$33.94M | - |
Definium Therapeutics, Inc. (DFTX) reported net income of -$183.79M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Definium Therapeutics, Inc.'s net income declined from -$33.94M to -$183.79M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.